Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.62 |
| ▸ | RAB9A | P51151 | 3/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.62 |
| ▸ | BACE1 | P56817 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 2/20 | 0.55 |
| ▸ | PRMT5 | O14744 | 3/20 | 0.51 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.51 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ITGAV | P06756 | 5/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | CTSG | P08311 | 1/20 | 0.45 |
| ▸ | CTRB1 | P17538 | 1/20 | 0.45 |
| ▸ | CMA1 | P23946 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153998 | 1.00 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2BACE1GAA | |
| SCHEMBL3465056 | 0.84 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2BACE1GAA | |
| SCHEMBL6154030 | 0.84 | NPC1 (0.64) | NPC1RAB9ASMN1; SMN2BACE1GAA | |
| SCHEMBL9253556 | 0.82 | NPC1 (0.57) | NPC1RAB9ASMN1; SMN2BACE1GAA | |
| SCHEMBL9830287 | 0.82 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2BACE1GAA | |
| Hydrochloric Acid SCHEMBL27854881 | 0.82 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2BACE1GAA | |
| SCHEMBL29280658 | 0.82 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2BACE1GAA | |
| SCHEMBL28341767 | 0.82 | NPC1 (0.62) | NPC1RAB9ASMN1; SMN2BACE1GAA | |
| SCHEMBL7561649 | 0.81 | NPC1 (0.70) | NPC1RAB9ASMN1; SMN2BACE1GAA | |
| SCHEMBL11451182 | 0.79 | SMN1; SMN2 (0.58) | NPC1RAB9ASMN1; SMN2BACE1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050215801-A1 | Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for synthesis thereof and process for preparation of the intermediates | KANEKA CORPORATION (JP) | 2005-09-29 | — | — | US | disclosed |
| EP-1553093-A1 | PROCESS FOR PREPARATION OF OPTICALLY ACTIVE 1-SUBSTITUTED AMINO-2,3-EPOXYPROPANES, INTERMEDIATES FOR THE SYNTHESIS THEREOF AND PROCESS FOR PREPARATION OF THE INTERMEDIATES | KANEKA CORPORATION (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050215801-A1 | Process for preparation of optically active 1-substituted amino-2,3-epoxypropanes, intermediates for synthesis thereof and process for preparation of the intermediates | OXER1, RCC2, CBR3 | NPC1 4434/4885RAB9A 2449/4885SMN1; SMN2 4620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.